Kadimastem - Stem Cell to Cure Diseases

Technology > Drug Discovery

Based on its experience in drug High Content Screening (HCS), primarily in Hit-to-Lead (H2L) screening. Kadimastem is currently seeking to develop “in-house” drug discovery capabilities that will enable it to identify Hit compounds.